SCHEMBL418006

SCHEMBL418006

O=C(COc1cccc(-c2ccccc2)c1)Nc1ccc(-c2ccccc2)cc1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.65
DVL1 O14640 1/20 0.61
KMT2A Q03164 5/20 0.59
MEN1 O00255 3/20 0.59
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
PTPN1 P18031 1/20 0.57
HCAR2 Q8TDS4 4/20 0.56
ALDH1A1 P00352 4/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
KDM4E B2RXH2 3/20 0.55
LMNA P02545 1/20 0.55
PLA2G1B P04054 1/20 0.55
ATG4B Q9Y4P1 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
MAPK10 P53779 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419348 0.90 SERPINE1 (0.79) SERPINE1DVL1KMT2AMEN1CASP3
SCHEMBL417355 0.90 SERPINE1 (0.81) SERPINE1DVL1KMT2AMEN1CASP3
SCHEMBL416414 0.89 ALDH1A1 (0.65) SERPINE1DVL1KMT2AMEN1CASP3
SCHEMBL1799401 0.85 PTPN1 (0.64) SERPINE1KMT2AMEN1CASP3SENP8
SCHEMBL2274054 0.84 HCAR2 (0.59) KMT2AMEN1CASP3SENP8SENP7
SCHEMBL3556566 0.84 SERPINE1 (0.53) SERPINE1DVL1KMT2AMEN1CASP3
SCHEMBL5696440 0.83 HCAR2 (0.76) KMT2AMEN1CASP3SENP8SENP7
SCHEMBL417064 0.83 SERPINE1 (0.71) SERPINE1DVL1KMT2AMEN1CASP3
SCHEMBL420814 0.82 SERPINE1 (0.66) SERPINE1KMT2AMEN1CASP3SENP8
SCHEMBL419088 0.82 SERPINE1 (0.76) SERPINE1DVL1KMT2AMEN1HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885DVL1 3200/4885KMT2A 3323/4885
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885DVL1 4030/4885KMT2A 4433/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885DVL1 4030/4885KMT2A 4433/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885DVL1 3530/4885KMT2A 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.